Table 8. Ongoing clinical trials of the seven novel agents.
| Agent | Phase | Other agents | Tumor type | Trial ID | |||
|---|---|---|---|---|---|---|---|
| Bevacizumab | I | Cediranib | Solid | NCT00458731 | |||
| I † | Everolimus | Solid | NCT00756340 | ||||
| I/II | VCR/IRN/TMZ | Solid | NCT00786669 | ||||
| I † | Sorafenib/CPM | Solid/leuk | NCT00665990 | ||||
| II | Chemo | Sarcomas | NCT00643565 | ||||
| II † | Temsirolimus, vinorelbine/CPM | RMS | NCT01222715 | ||||
| II | CHEMO/RT | RMS | NCT01871766 | ||||
| II | – | NF–2 | NCT01767792 | ||||
| II | – | NF–2 | NCT01207687 | ||||
| I | – | NB | NCT00450827 | ||||
| I | CPM/zoledronic acid | NB | NCT00885326 | ||||
| II | IRN/TMZ | NB | NCT01114555 | ||||
| II | CPM/topotecan | ES/NB | NCT01492673 | ||||
| III | VCR/topotecan/CPM | ES | NCT00516295 | ||||
| I † | Sorafenib, temsirolimus | ES/DSRCT | NCT01946529 | ||||
| Pilot | IRN/TMZ/chemo | DSRCT | NCT01189643 | ||||
| II | Chemo | OS | NCT00667342 | ||||
| II | Chemo | GCT | NCT00936936 | ||||
| II | IRN | CNS | NCT00381797 | ||||
| II | Chemo | MB | NCT01356290 | ||||
| II | Chemo | MB | NCT01356290 | ||||
| II | IRN/TMZ | MB/PNET | NCT01217437 | ||||
| II | TMZ/RT | HGG | NCT01390948 | ||||
| II | Valproic acid/RT | HGG | NCT00879437 | ||||
| II/III † | TMZ/vorinostat/RT | HGG | NCT01236560 | ||||
| Pilot | IRN/TMZ | HGG, DIPG | NCT00890786 | ||||
| II † | Erlotinib/TMZ/RT | DIPG | NCT01182350 | ||||
| I/II | Cetuximab | Glioma | NCT01884740 | ||||
| II | Lapatinib | EPM | NCT00883688 | ||||
| Bortezomib | I | IRN | NB | NCT00644696 | |||
| II | – | ALL | NCT00873093 | ||||
| II | – | ALL | NCT00440726 | ||||
| II | Arsenic | APL | NCT01950611 | ||||
| III † | Sorafenib | AML | NCT01371981 | ||||
| Vorinostat | I/II | – | Solid | NCT01294670 | |||
| I | Isotretinoin | MB/PNET | NCT00867178 | ||||
| I | Isotretinoin | NB | NCT01208454 | ||||
| I | 131-i-MIBG | NB | NCT01019850 | ||||
| I/II | Decitabine | ALL | NCT01483690 | ||||
| Sorafenib | I | Topotecan | Solid | NCT01683149 | |||
| I | IRN | Solid | NCT01518413 | ||||
| II | – | RMS/kidney liver/thyroid | NCT01502410 | ||||
| II | – | LGG | NCT01338857 | ||||
| II | Chemo/RT | RMS | NCT01871766 | ||||
| Erlotinib | I | Pralatrexate | Advanced | NCT01532011 | |||
| I | Radiotherapy | CNS | NCT00360854 | ||||
| I † | Sirolimus | LGG | NCT00901849 | ||||
| II † | Sirolimus | GCT | NCT01962896 | ||||
| III | Chemo | CNS | NCT00602667 | ||||
| mTOR inhibitors: sirolimus (S), temsirolimus (T), everolimus (E) | I (S) | – | ALL | NCT01658007 | |||
| I (S) | – | Leuk/NHL | NCT00068302 | ||||
| I (S) | – | Solid | NCT01331135 | ||||
| I (S) | Topotecan | Solid | NCT01670175 | ||||
| I (S) | IRN | Solid | NCT01282697 | ||||
| II (S) | – | NF-1 | NCT00634270 | ||||
| II (S) | Dasatinib, IRN/TMZ | NB | NCT01467986 | ||||
| I (T) | – | ALL/NHL | NCT01403415 | ||||
| I (T) | Etoposide/CPM | ALL/NHL | NCT01614197 | ||||
| I (T) | Perifosine | Solid | NCT01049841 | ||||
| I (T) | Cixutumumab | Sarcoma | NCT01614795 | ||||
| II (T) | IRN/TMZ/ch14.18 | NB | NCT01767194 | ||||
| I (E) | – | ALL | NCT01523977 | ||||
| I (E) | – | NF-2 | NCT01419639 | ||||
| I(E) | – | LGG | NCT01158651 | ||||
| II (E) | – | LGG | NCT01734512 | ||||
| II (E) | – | OS | NCT01216826 | ||||
| II (E) | – | Sarcomas | NCT01216839 | ||||
Chemo, chemotherapy; CPM, cyclophosphamide; DIPG, diffuse intrinsic pontine glioma; DSRCT, desmoplastic small round cell tumor; EPM, eppendymoma; GCT, germ cell tumor; HGG, high-grade glioma; IRN, irinotecan; leuk, leukemia; NF1, neurofibromatosis type-1-related plexiform neurofibroma; NF2, neurofibromatosis type-2-related vestibular schwannomas; OS, osteosarcoma; RMS, rhabdomyosarcoma; RT, radiotherapy; TMZ, temozolomide; VCR, vincristine; †, trial involving 2 or more of the 6 novel agents.